دورية أكاديمية
Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer
| العنوان: | Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer |
|---|---|
| المؤلفون: | Lu Wanjun, Liu Lixia, Kang Xiang, Ren Kangkang, Huang Ye, Cheng Minzhang, Li Xiaolei, Xu Fei, Xu Xinping |
| المصدر: | Acta Biochimica et Biophysica Sinica, Vol 56, Pp 1022-1033 (2024) |
| بيانات النشر: | China Science Publishing & Media Ltd., 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Biochemistry LCC:Genetics |
| مصطلحات موضوعية: | cetuximab, STA9090, synergistic effect, receptor tyrosine kinase, non-small cell lung cancer, Biochemistry, QD415-436, Genetics, QH426-470 |
| الوصف: | Cetuximab (CET), a human murine chimeric IgG monoclonal antibody and an inhibitor of epidermal growth factor receptor (EGFR), has been shown to be effective in treating various types of cancer. However, its use is hindered by limitations such as resistance development, variability in patient response, side effects, and challenges in biomarker identification. Therefore, CET is often combined with other targeted therapies or chemotherapies to enhance its effectiveness. In this study, we investigate the anticancer effects and underlying mechanisms of the combination of CET, an EGFR inhibitor, and STA9090, an inhibitor of heat shock protein 90 (Hsp90), in both in vitro and in vivo models of non-small cell lung cancer (NSCLC). The results demonstrate significantly stronger effects on NSCLC cells in response to combination therapy than to treatment with either agent alone, indicating that the combination of CET and STA9090 has potential synergistic effects. Additionally, the combination therapy inhibits tumor growth in a xenograft nude mouse model more effectively than treatment with either agent alone, suggesting improved efficacy when used together. Furthermore, the synergistic effects of the combination therapy are likely due to inactivation of the receptor tyrosine kinase (RTK) pathway, which is overly activated in cancer and contributes to tumor growth, angiogenesis, and metastasis. Consequently, our findings suggest that STA9090 has potent direct antitumor activity and synergizes with CET against NSCLC tumors. It is highly likely that these synergistic effects are mediated through RTK pathway inactivation caused by the combination. Therefore, our findings strongly and consistently support the potential synergistic effect of STA9090, an RTK inhibitor, in combination with EGFR-targeting agents. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1672-9145 |
| Relation: | https://doaj.org/toc/1672-9145 |
| DOI: | 10.3724/abbs.2024069 |
| URL الوصول: | https://doaj.org/article/e6cf17bcdd6e49a1aa6387c59b46322e |
| رقم الأكسشن: | edsdoj.6cf17bcdd6e49a1aa6387c59b46322e |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 16729145 |
|---|---|
| DOI: | 10.3724/abbs.2024069 |